{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:15:40Z","timestamp":1790435740637,"version":"4.1.0"},"reference-count":55,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"unspecified","delay-in-days":25,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"national institute of health","award":["CA215523"],"award-info":[{"award-number":["CA215523"]}]},{"name":"national institute of health","award":["CA238514"],"award-info":[{"award-number":["CA238514"]}]},{"name":"national institute of health","award":["CA264983"],"award-info":[{"award-number":["CA264983"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,6,26]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adoptive cell therapy (ACT) using genetically modified T cells has evolved into a promising treatment option for patients with cancer. However, even for the best-studied and clinically validated CD19-targeted chimeric antigen receptor (CAR) T-cell therapy, many patients face the challenge of lack of response or occurrence of relapse. There is increasing need to improve the efficacy of ACT so that durable, curative outcomes can be achieved in a broad patient population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Here, we investigated the impact of indomethacin (indo), a non-steroidal anti-inflammatory drug (NSAID), on the efficacy of ACT in multiple preclinical models. Mice with established B-cell lymphoma received various combinations of preconditioning chemotherapy, infusion of suboptimal dose of tumor-reactive T cells, and indo administration. Donor T cells used in the ACT models included CD4<jats:sup>+<\/jats:sup> T cells expressing a tumor-specific T cell receptor (TCR) and T cells engineered to express CD19CAR. Mice were monitored for tumor growth and survival. The effects of indo on donor T cell phenotype and function were evaluated. The molecular mechanisms by which indo may influence the outcome of ACT were investigated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>ACT coupled with indo administration led to improved tumor growth control and prolonged mouse survival. Indo did not affect the activation status and tumor infiltration of the donor T cells. Moreover, the beneficial effect of indo in ACT did not rely on its inhibitory effect on the immunosuppressive cyclooxygenase 2 (COX2)\/prostaglandin E2 (PGE2) axis. Instead, indo-induced oxidative stress boosted the expression of death receptor 5 (DR5) in tumor cells, rendering them susceptible to donor T cells expressing TNF-related apoptosis-inducing ligand (TRAIL). Furthermore, the ACT-potentiating effect of indo was diminished against DR5-deficient tumors, but was amplified by donor T cells engineered to overexpress TRAIL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our results demonstrate that the pro-oxidative property of indo can be exploited to enhance death receptor signaling in cancer cells, providing rationale for combining indo with genetically modified T cells to intensify tumor cell killing through the TRAIL-DR5 axis. These findings implicate indo administration, and potentially similar use of other NSAIDs, as a readily applicable and cost-effective approach to augment the efficacy of ACT.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-004938","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T12:54:39Z","timestamp":1658840079000},"page":"e004938","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Indomethacin-induced oxidative stress enhances death receptor 5 signaling and sensitizes tumor cells to adoptive T-cell therapy"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-9897","authenticated-orcid":false,"given":"Nada S","family":"Aboelella","sequence":"first","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Brandle","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogacheko","family":"Okoko","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Yeashin","family":"Gazi","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Chun","family":"Ding","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Xu","sequence":"additional","affiliation":[{"name":"Division of Biostatistics & Data Science, Department of Population Health Sciences, Medical College of Georgia, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4306-8884","authenticated-orcid":false,"given":"Gregory","family":"Gorman","sequence":"additional","affiliation":[{"name":"McWhorter School of Pharmacy, Samford University, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Bollag","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"},{"name":"Department of Pathology, Medical College of Georgia, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-3065","authenticated-orcid":false,"given":"Marco L","family":"Davila","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant & Cellular Immunotherapy Department, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Locke J","family":"Bryan","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"},{"name":"Department of Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Munn","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"},{"name":"Department of Pediatrics, Medical College of Georgia, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A","family":"Piazza","sequence":"additional","affiliation":[{"name":"Drug Discovery and Development, Harrison School of Pharmacy, Auburn University, Auburn, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-114X","authenticated-orcid":false,"given":"Gang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Augusta University, Augusta, Georgia, USA"},{"name":"Department of Medicine, Medical College of Georgia, Augusta University, Augusta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2025100305270698000_10.7.e004938.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041407"},{"key":"2025100305270698000_10.7.e004938.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.001"},{"key":"2025100305270698000_10.7.e004938.3","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14712598.2019.1608179","article-title":"Facing the future: challenges and opportunities in adoptive T cell therapy in cancer","volume":"19","author":"Magalhaes","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"2025100305270698000_10.7.e004938.4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"2025100305270698000_10.7.e004938.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0564-6"},{"key":"2025100305270698000_10.7.e004938.6","doi-asserted-by":"publisher","DOI":"10.2741\/1667"},{"key":"2025100305270698000_10.7.e004938.7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13050986","article-title":"Oxidative stress in the tumor microenvironment and its relevance to cancer immunotherapy","volume":"13","author":"Aboelella","year":"2021","journal-title":"Cancers"},{"key":"2025100305270698000_10.7.e004938.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2803"},{"key":"2025100305270698000_10.7.e004938.9","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4002"},{"key":"2025100305270698000_10.7.e004938.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1424"},{"key":"2025100305270698000_10.7.e004938.11","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.7.12.7067"},{"key":"2025100305270698000_10.7.e004938.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.08.015"},{"key":"2025100305270698000_10.7.e004938.13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cmet.2018.05.012","article-title":"Alteration of tumor metabolism by CD4+ T cells leads to TNF-\u03b1-dependent intensification of oxidative stress and tumor cell death","volume":"28","author":"Habtetsion","year":"2018","journal-title":"Cell Metab"},{"key":"2025100305270698000_10.7.e004938.14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4401436"},{"key":"2025100305270698000_10.7.e004938.15","first-page":"437","article-title":"Nonsteroidal anti-inflammatory drugs and oxidative stress in cancer cells","volume":"22","author":"Adachi","year":"2007","journal-title":"Histol Histopathol"},{"key":"2025100305270698000_10.7.e004938.16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/ph8010062","article-title":"Hitting the bull's-eye in metastatic cancers-NSAIDs elevate ROS in mitochondria, inducing malignant cell death","volume":"8","author":"Ralph","year":"2015","journal-title":"Pharmaceuticals"},{"key":"2025100305270698000_10.7.e004938.17","first-page":"1731","article-title":"Endoplasmic reticulum stress response as a possible mechanism of cyclooxygenase-2-independent anticancer effect of celecoxib","volume":"34","author":"Cha","year":"2014","journal-title":"Anticancer Res"},{"key":"2025100305270698000_10.7.e004938.18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005804"},{"key":"2025100305270698000_10.7.e004938.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.06.016"},{"key":"2025100305270698000_10.7.e004938.20","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/jid.2013.471","article-title":"Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin","volume":"134","author":"Tse","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2025100305270698000_10.7.e004938.21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bcp.2018.05.013","article-title":"Celecoxib inhibits mitochondrial O\n                  2\n                consumption, promoting ROS dependent death of murine and human metastatic cancer cells via the apoptotic signalling pathway","volume":"154","author":"Pritchard","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"2025100305270698000_10.7.e004938.22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.20517\/2394-4722.2018.42","article-title":"NSAID celecoxib: a potent mitochondrial pro-oxidant cytotoxic agent sensitizing metastatic cancers and cancer stem cells to chemotherapy","volume":"4","author":"Ralph","year":"2018","journal-title":"J Cancer Metastasis Treat"},{"key":"2025100305270698000_10.7.e004938.23","doi-asserted-by":"crossref","DOI":"10.3390\/biology9120434","article-title":"Prostaglandin E2 and cancer: insight into tumor progression and immunity","volume":"9","author":"Finetti","year":"2020","journal-title":"Biology"},{"key":"2025100305270698000_10.7.e004938.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2012.02.003"},{"key":"2025100305270698000_10.7.e004938.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.015"},{"key":"2025100305270698000_10.7.e004938.26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1815"},{"key":"2025100305270698000_10.7.e004938.27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060200","article-title":"Overcoming resistance of human non-hodgkin\u2019s lymphoma to CD19-CAR CTL therapy by celecoxib and histone deacetylase inhibitors","volume":"10","author":"Torres-Collado","year":"2018","journal-title":"Cancers"},{"key":"2025100305270698000_10.7.e004938.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-398321"},{"key":"2025100305270698000_10.7.e004938.29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253336"},{"key":"2025100305270698000_10.7.e004938.30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-01-265041"},{"key":"2025100305270698000_10.7.e004938.31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1171445","article-title":"IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells","volume":"5","author":"Ding","year":"2016","journal-title":"Oncoimmunology"},{"key":"2025100305270698000_10.7.e004938.32","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0253"},{"key":"2025100305270698000_10.7.e004938.33","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-29"},{"key":"2025100305270698000_10.7.e004938.34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806849105"},{"key":"2025100305270698000_10.7.e004938.35","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba5962","article-title":"Persistent STAT5 activation reprograms the epigenetic landscape in CD4+ T cells to drive polyfunctionality and antitumor immunity","volume":"5","author":"Ding","year":"2020","journal-title":"Sci Immunol"},{"key":"2025100305270698000_10.7.e004938.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2809"},{"key":"2025100305270698000_10.7.e004938.37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008455"},{"key":"2025100305270698000_10.7.e004938.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0801868105"},{"key":"2025100305270698000_10.7.e004938.39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2305"},{"key":"2025100305270698000_10.7.e004938.40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-03459-5","article-title":"Fibroblastic reticular cells of the lymphoid tissues modulate T cell activation threshold during homeostasis via hyperactive cyclooxygenase-2\/prostaglandin E\n                  2\n                axis","volume":"7","author":"Yu","year":"2017","journal-title":"Sci Rep"},{"key":"2025100305270698000_10.7.e004938.41","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.drudis.2020.06.008","article-title":"PDE5 and PDE10 inhibition activates cGMP\/PKG signaling to block Wnt\/\u03b2-catenin transcription, cancer cell growth, and tumor immunity","volume":"25","author":"Piazza","year":"2020","journal-title":"Drug Discov Today"},{"key":"2025100305270698000_10.7.e004938.42","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12238"},{"key":"2025100305270698000_10.7.e004938.43","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.81"},{"key":"2025100305270698000_10.7.e004938.44","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2015.174"},{"key":"2025100305270698000_10.7.e004938.45","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-018-9728-y"},{"key":"2025100305270698000_10.7.e004938.46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11070954","article-title":"Molecular mode of action of TRAIL receptor agonists-common principles and their translational exploitation","volume":"11","author":"Wajant","year":"2019","journal-title":"Cancers"},{"key":"2025100305270698000_10.7.e004938.47","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.628332","article-title":"The TRAIL in the treatment of human cancer: an update on clinical trials","volume":"8","author":"Snajdauf","year":"2021","journal-title":"Front Mol Biosci"},{"key":"2025100305270698000_10.7.e004938.48","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3501"},{"key":"2025100305270698000_10.7.e004938.49","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66301"},{"key":"2025100305270698000_10.7.e004938.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.09.008"},{"key":"2025100305270698000_10.7.e004938.51","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"key":"2025100305270698000_10.7.e004938.52","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0813"},{"key":"2025100305270698000_10.7.e004938.53","doi-asserted-by":"publisher","DOI":"10.1038\/nature03337"},{"key":"2025100305270698000_10.7.e004938.54","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0410-2"},{"key":"2025100305270698000_10.7.e004938.55","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401710"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-004938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:27:17Z","timestamp":1759494437000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-004938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,26]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/jitc-2022-004938"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-004938","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}